$146.00
Manufacturer: Ukraine
Treatment of adult patients with type II diabetes. As monotherapy: for patients in whom the use of diet and exercise alone does not provide sufficient control, as well as for patients in whom the use of Metformin is considered unacceptable due to contraindications or intolerance. As part of double oral therapy in combination with : Metformin for patients with insufficient glycemic control, despite the use of the maximum tolerated dose during Metformin monotherapy;
Description
Gliptar Composition
active substance: vildagliptin;
1 tablet contains vildagliptin 50 mg;
excipients: microcrystalline cellulose, anhydrous lactose, sodium starch glycolate (type A), magnesium stearate.
Gliptar Dosage form
Pills.
Basic physical and chemical properties: tablets from white to light yellow, round in shape with a flat surface, with a line.
Gliptar Pharmacotherapeutic group
Hypoglycemic synthetic and other substances. Dipeptidyl peptidase-4 inhibitors. ATX code A10B H02.
Pharmacodynamics
Vildagliptin belongs to a class of substances that enhance the work of beta cells of the islet apparatus of the pancreas, is a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4).
The use of vildagliptin leads to a rapid and complete cessation of DPP-4 activity. Inhibition of DPP-4 by vildagliptin leads to an increase in endogenous levels of the hormones incretin GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide) during fasting and after meals.
Indications
Treatment of adult patients with type II diabetes mellitus.
As monotherapy:
for patients in whom the use of diet and exercise alone does not provide sufficient control, as well as for patients in whom the use of metformin is considered unacceptable due to the presence of contraindications or intolerance.
As part of oral double therapy in combination with:
metformin for patients with insufficient glycemic control, despite the use of the maximum tolerated dose during metformin monotherapy;
sulfonylurea for patients with insufficient glycemic control, despite the use of the maximum tolerated dose of sulfonylurea, and for patients for whom the use of metformin is considered unacceptable due to the presence of contraindications or intolerance;
thiazolidinedione for patients with insufficient glycemic control for whom the use of thiazolidinedione is considered acceptable.
As part of triple oral therapy in combination with:
sulfonylurea and metformin when diet and exercise combined with dual therapy with these drugs do not provide adequate glycemic control.
In combination with insulin (with or without metformin), when diet and exercise together with a stable dose of insulin do not provide adequate glycemic control.
Contraindications
Hypersensitivity to vildagliptin or to an excipient.
Recent Reviews